Kerendia Tablet, Film Coated
Product Images NDC 50419-540

9 FDA label images from Bayer Healthcare Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Kerendia (NDC 50419-540). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bayer Healthcare Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Kerendia 01)

Chemical Structure (Kerendia 01)
Chemical structure of Finerenone, showing its molecular framework with rings, functional groups including a nitrile group, amide, and ether linkages, depicted using standard organic chemistry notation.*
FDA Label Image

Figure 1 (Kerendia 02)

Figure 1 (Kerendia 02)
A line graph showing cumulative incidence probability over time to first event (months) comparing Kerendia (Finerenone) and placebo groups. The x-axis shows months up to 42, and the y-axis shows cumulative incidence probability up to 0.4. The graph includes numbers of patients at risk for both groups at multiple time points.*
FDA Label Image

Figure 2 (Kerendia 03)

Figure 2 (Kerendia 03)
A Kaplan-Meier cumulative incidence probability curve comparing planned treatment with Kerendia (Finerenone) and placebo over time to the first event measured in months, up to 54 months. The graph shows patient numbers at risk for both groups at various time points. Kerendia group includes 3686 patients; placebo group includes 3666 patients.*
FDA Label Image

Figure 3 (Kerendia 04)

Figure 3 (Kerendia 04)
A line graph displaying the cumulative incidence probability over time (in months) to first event for two treatment groups: Kerendia (N=2833) and placebo (N=2841). The graph includes a risk table showing the number of patients at risk at various time points up to 42 months for both groups. Kerendia is represented by a solid blue line and placebo by a dashed red line.*
FDA Label Image

Figure 4 (Kerendia 05)

Figure 4 (Kerendia 05)
A line graph showing cumulative incidence probability over time to first event in months for two groups: Kerendia (N=3686) and Placebo (N=3666). The Kerendia group is represented by a solid blue line, while the Placebo group is shown by a dashed red line, with the latter showing higher cumulative incidence over time. Below the graph, the number of patients at risk for each group is listed at various time points from 0 to 54 months.*
FDA Label Image

Figure 5 (Kerendia 06)

Figure 5 (Kerendia 06)
A Kaplan-Meier plot depicting mean cumulative function over time in months, comparing Finerenone treatment (N=3003) and placebo (N=2998) groups. The plot shows two lines: a solid blue line for Finerenone and a dotted red line for placebo. The chart includes a table beneath showing the number of subjects at risk at various time points up to 42 months.*
FDA Label Image

Principal Display Panel- 10 mg Tablet Carton (Kerendia 07)

Principal Display Panel- 10 mg Tablet Carton (Kerendia 07)
Packaging label for Kerendia (finerenone) tablets, 10 mg strength. The label indicates the product form as film-coated tablets with a package size of 30 tablets. It is manufactured for Bayer HealthCare Pharmaceuticals Inc. The label includes storage instructions and a barcode.*
FDA Label Image

Principal Display Panel- 20 mg Tablet Carton (Kerendia 08)

Principal Display Panel- 20 mg Tablet Carton (Kerendia 08)
Packaging label for Kerendia (finerenone) tablets, 20 mg strength. The label indicates 30 film-coated tablets per package. It includes the NDC 50419-541-01 and shows Bayer HealthCare Pharmaceuticals Inc. as the manufacturer, with the product made in Germany. The label features dosage storage instructions and warnings about keeping out of reach of children.*
FDA Label Image

Principal Display Panel- 40 mg Tablet Carton (Kerendia 09)

Principal Display Panel- 40 mg Tablet Carton (Kerendia 09)
Packaging label for Kerendia (finerenone) tablets 40 mg by Bayer HealthCare Pharmaceuticals Inc. The label states each film-coated tablet contains 40 mg finerenone and comes in a package of 30 tablets. It includes storage instructions, barcodes, NDC code 50419-542-01, manufacturing details indicating production in Germany, and Bayer branding.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.